EpiVax Inc - Company Profile
Powered by 
All the sales intelligence you need on EpiVax Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how EpiVax Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with EpiVax Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T-cells. It is an immune-modulation power tool that is being developed for auto-immune, auto-inflammatory, and allergic conditions. EpiVax’s service portfolio includes immune engineering, immunogenicity screening, vaccine design, and redesign. The company also provides lab services such as in vivo, in vitro and ex vivo immunogenicity screening services including cell-free HLA binding assays. EpiVax is headquartered in Providence, Rhode Island, the US.
Headquarters
United States of America
Address
Suite 424, 188 Valley Street, Providence, Rhode Island, 02909
Website
www.epivax.com
Telephone
1 401 2722123
Industry
Pharmaceuticals and Healthcare
EpiVax Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Product Pipeline: | Vaccine Design and Redesign | ISPRI |
| Tregitope- Immuno-Modulation Power Tool | Immunogenicity Screening | ISPRI Downselect |
| Deimmunized Botox- Deimmunization | Immune Engineering | ISPRI Quantify |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In October, the company along with CUBRC secured a two-year US$2 million contract from the Office of Generic Drugs of the Food and Drug Administration to develop standardized controls. |
| 2023 | Contracts/Agreements | In January, the company and Zoetis announced their agreement to collaborate on Swine T cell Epitope Prediction Tool: CircoMatch. |
| 2023 | Contracts/Agreements | In January, the company and Greenlight announced their agreement to develop personalized cancer vaccines. |
Competitor Comparison
| Key Parameters | EpiVax Inc | Jounce Therapeutics Inc | VBI Vaccines Inc | Advanced BioScience Laboratories Inc | BioFactura Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Providence | Cambridge | Cambridge | Rockville | Frederick |
| State/Province | Rhode Island | Massachusetts | Massachusetts | Maryland | Maryland |
| No. of Employees | - | 141 | 131 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rich-Henry Schabowsky, Ph.D. | Chief Executive Officer | Senior Management | 2024 | - |
| Anne S. De Groot, Ph.D., M.D. | Chief Medical Officer | Senior Management | 2025 | - |
| Vibha Jawa, PhD | Chief Scientific Officer | Senior Management | 2025 | - |
| Christine Boyle, Ph.D. | Chief Scientific Operations Officer | Senior Management | - | - |
| Brad Crevier | Chief Financial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer